Skip to content
Subscriber Only

Pfizer Study Finds Progress in Combating Fatty Liver

  • Fructose-inhibiting therapy reduced liver fat by 26.5 percent
  • Drugmaker takes metabolic approach to common disease
A worker tests a liquid chemical inside of a laboratory at the Pfizer Inc. research and development facility in Cambridge, Massachusetts, U.S., on Monday, Oct. 26, 2015. Pfizer is expected to report quarterly earnings on October 27.
Photographer: Bloomberg/Bloomberg

Pfizer Inc. said that results from a midstage, six-week study of its drug that prevents the body from metabolizing fructose, a natural sugar found in fruits and vegetables, showed a statistically significant improvement in liver fat.

The medication, an inhibitor of the fructokinase enzyme, could reverse or prevent the progression of the liver disease nonalcoholic steatohepatitis, known as NASH, and perhaps even treat diabetes, according to the company.